363 related articles for article (PubMed ID: 30195076)
21. Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee.
Januzzi JL; Garasic JM; Kasner SE; McDonald V; Petrie MC; Seltzer J; Mauro M; Croce K; Berman E; Deininger M; Hochhaus A; Pinilla-Ibarz J; Nicolini F; Kim DW; DeAngelo DJ; Kantarjian H; Xu J; Hall T; Srivastava S; Naranjo D; Cortes J
J Hematol Oncol; 2022 Jan; 15(1):1. PubMed ID: 34991679
[TBL] [Abstract][Full Text] [Related]
22. Ponatinib: A Third-Generation Inhibitor for the Treatment of CML.
Wehrle J; von Bubnoff N
Recent Results Cancer Res; 2018; 212():109-118. PubMed ID: 30069627
[TBL] [Abstract][Full Text] [Related]
23. The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Sanford DS; Kantarjian H; O'Brien S; Jabbour E; Cortes J; Ravandi F
Expert Rev Anticancer Ther; 2015 Apr; 15(4):365-73. PubMed ID: 25764322
[TBL] [Abstract][Full Text] [Related]
24. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
Lipton JH; Chuah C; Guerci-Bresler A; Rosti G; Simpson D; Assouline S; Etienne G; Nicolini FE; le Coutre P; Clark RE; Stenke L; Andorsky D; Oehler V; Lustgarten S; Rivera VM; Clackson T; Haluska FG; Baccarani M; Cortes JE; Guilhot F; Hochhaus A; Hughes T; Kantarjian HM; Shah NP; Talpaz M; Deininger MW;
Lancet Oncol; 2016 May; 17(5):612-21. PubMed ID: 27083332
[TBL] [Abstract][Full Text] [Related]
25. Ponatinib (Iclusig) for CML and Ph+ ALL.
Med Lett Drugs Ther; 2013 Sep; 55(1424):71-2. PubMed ID: 25970013
[No Abstract] [Full Text] [Related]
26. Long-Term Follow-Up in Patients With Chronic Myeloid Leukemia Treated With Ponatinib in a Real-World Cohort: Safety and Efficacy Analysis.
Mela Osorio MJ; Moiraghi B; Osycka MV; Pavlovsky MA; Varela AI; Bendek Del Prete GE; Tosin MF; Pérez MA; Riva ME; Berrios RR; Fernández I; Sackmann Massa F; Giere I; Sighel C; Pavlovsky C
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):158-164. PubMed ID: 37973457
[TBL] [Abstract][Full Text] [Related]
27. Ponatinib: a third-generation inhibitor for the treatment of CML.
Wehrle J; Pahl HL; von Bubnoff N
Recent Results Cancer Res; 2014; 201():99-107. PubMed ID: 24756787
[TBL] [Abstract][Full Text] [Related]
28. Management of Ponatinib in Patients with Chronic Myeloid Leukemia with Cardiovascular Risk Factors.
Santoro M; Accurso V; Mancuso S; Contrino AD; Sardo M; Novo G; Di Piazza F; Perez A; Russo A; Siragusa S
Chemotherapy; 2019; 64(4):205-209. PubMed ID: 31825920
[TBL] [Abstract][Full Text] [Related]
29. Ponatinib in the therapy of chronic myeloid leukemia.
Poch Martell M; Sibai H; Deotare U; Lipton JH
Expert Rev Hematol; 2016 Oct; 9(10):923-32. PubMed ID: 27590270
[TBL] [Abstract][Full Text] [Related]
30. Ponatinib in the leukemia world: why a reevaluation is necessary for Philadelphia chromosome-positive patients with T315I mutation.
Goodrich AD
Expert Rev Hematol; 2014 Oct; 7(5):513-5. PubMed ID: 25199408
[TBL] [Abstract][Full Text] [Related]
31. [Chronic myeloid leukemia harboring T315I and F317L mutations successfully treated with interferon-α and ponatinib].
Motomura Y; Arai K; Yoshifuji K; Sonokawa S; Suzuki S; Kumagai T
Rinsho Ketsueki; 2019; 60(1):33-38. PubMed ID: 30726822
[TBL] [Abstract][Full Text] [Related]
32. Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib.
Breccia M; Efficace F; Iurlo A; Luciano L; Abruzzese E; Gozzini A; Pregno P; Tiribelli M; Rosti G; Minotti G
Expert Opin Drug Saf; 2018 Jun; 17(6):623-628. PubMed ID: 29845876
[TBL] [Abstract][Full Text] [Related]
33. Salvage and bridging to allogeneic hematopoietic cell transplantation with ponatinib in patients with relapsed or refractory Philadelphia chromosome-positive leukemia.
Tachibana T; Koyama S; Andou T; Ishiyama Y; Tanaka M; Nakajima H; Kanamori H
Int J Hematol; 2019 Feb; 109(2):162-168. PubMed ID: 30511314
[TBL] [Abstract][Full Text] [Related]
34. [Ponatinib: new option for the treatment of resistant chronic myeloid leukemia].
Camañas-Troyano C; Calderón-Acedos C; Moriel-Sánchez Mdel C; Segura-Bedmar M
Farm Hosp; 2013; 37(5):428-9. PubMed ID: 24128110
[No Abstract] [Full Text] [Related]
35. BCR-ABL1 compound mutations drive ponatinib resistance.
Cancer Discov; 2014 Nov; 4(11):OF13. PubMed ID: 25367954
[TBL] [Abstract][Full Text] [Related]
36. Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia.
Haddad FG; Issa GC; Jabbour E; Yilmaz M
Expert Opin Pharmacother; 2022 May; 23(7):751-758. PubMed ID: 35412404
[TBL] [Abstract][Full Text] [Related]
37. Ponatinib Tyrosine Kinase Inhibitor Induces a Thromboinflammatory Response.
Hamadi A; Grigg AP; Dobie G; Burbury KL; Schwarer AP; Kwa FA; Jackson DE
Thromb Haemost; 2019 Jul; 119(7):1112-1123. PubMed ID: 31079415
[TBL] [Abstract][Full Text] [Related]
38. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
39. Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis.
Fachi MM; Tonin FS; Leonart LP; Aguiar KS; Lenzi L; Figueiredo BC; Fernandez-Llimos F; Pontarolo R
Eur J Cancer; 2018 Nov; 104():9-20. PubMed ID: 30296736
[TBL] [Abstract][Full Text] [Related]
40. The Outcomes of Ponatinib Therapy in Patients With Chronic Myeloid Leukemia Resistant or Intolerant to Previous Tyrosine Kinase Inhibitors, Treated in Poland Within the Donation Program.
Sacha T; Szczepanek E; Dumnicka P; Góra-Tybor J; Niesiobędzka-Krężel J; Prejzner W; Wasilewska E; Kłoczko J; Ciepłuch H; Makowska W; Patkowska E; Wasilewska J; Bober G; Kopera M; Wichary R; Kroll-Balcerzak R; Gromek T; Wach M; Rudkowska-Kazanowska A; Świniarska M; Paczkowska E; Biernat M; Joks M; Oller M; Kasza R; Kostyra A; Gil J; Grzybowska-Izydorczyk O
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):405-415. PubMed ID: 34933827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
